Monotherapy with PARP inhibitors for the treatment of recurrent ovarian cancer
| Trial name/identification | Phase | Treatment(s) | Disease setting | Sample size | Objective response rate (%) | Progression-free survival (median months) | Overall survival (median months) |
| Study 42 (Domchek et al. 2016)9 | II | Olaparib | Platinum-resistant/refractory or platinum-sensitive germline BRCA1/2-mutated ovarian cancer | 193 | 34% | 6.7 | Not reported |
| SOLO3 (Penson et al. 2020; Penson et al. 2022)11 12 | III | Olaparib vs non-platinum chemotherapy | Platinum-sensitive recurrent germline BCRA-mutated ovarian cancer | 266 | 72.2% vs 51.4% | 13.4 vs 9.2 | 34.9 vs 32.9 |
| Study 12/ICEBERG 3 (Kaye et al. 2012)13 | II | Plaparib 200 mg vs olaparib 400 mg vs liposomal doxorubicin | Platinum-sensitive/resistant recurrent germline BRCA-mutated ovarian cancer | 97 | 25% vs 31% vs 18% | 6.5 vs 8.8 vs 7.1 | Not reported |
| CLIO (Vanderstichele et al. 2019)14 | II | Olaparib vs physician’s choice chemotherapy | Platinum-resistant ovarian cancer | 100 | 18% vs 6% | 2.9 vs 3.4 | Not reported |
| LIGHT (Cadoo et al. 2020 & 2021; Mathews et al. 2021)15 16 59 | II | Olaparib | Platinum-sensitive recurrent, high-grade serous/endometrioid epithelial ovarian cancer | 271 | 37% | 7.4 | Not reported |
| ARIEL 4 (Kristeleit et al. 2021)20 | III | Rucaparib vs standard-of-care chemotherapy | Platinum-sensitive/resistant, high-grade germline BRCA/somatic-mutated recurrent ovarian cancer | 349 | 40.3% vs 32.3% | 7.4 vs 5.7 | Not reported |
| QUADRA (Moore et al. 2019)21 | II | Niraparib | Relapsed, high-grade serous (grade 2 or 3) ovarian cancer | 461 | 28% | 5.5 | 17.2 |
| Coleman et al. 201522 | II | Veliparib | Primary BRCA-mutated/germline BRCA ovarian cancer | 50 | 26% | 8.11 | 19.7 |
| Steffensen et al 201723 | I/II | Veliparib | Platinum-resistant or intermediate sensitive relapsed ovarian cancer | 45 | 44% | 5.6 | 13.7 |
BRCA, BReast CAncer gene; PARP, poly-ADP ribose polymerase.